NCT01676311

Effects of Huperzine A in Treatment of Moderate to Severe TBI

Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Spaulding Rehabilitation Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after TBI. Additionally, we aim to determine whether use of Huperzine A in these patients can change brain activity (as indexed by EEG and Transcranial Magnetic Stimulation - TMS), and reduce prevalence/frequency of post-traumatic seizures. We also aim to evaluate the safety of Huperzine A in this population as compared with placebo.

Conditions

• Traumatic Brain Injury

Interventions

Type	Name	Description
DRUG	Huperzine A	Huperzine A will be administered for 12 weeks as outlined in the Arm Description
DRUG	Placebo	Placebo Arm (blinded randomization) for Huperzine A Intervention

Timeline

• Start date: 2013-12-01
• Primary completion: 2018-08-01
• Completion: 2018-08-01
• First posted: 2012-08-30
• Last updated: 2019-11-05
• Results posted: 2019-10-07

Locations

1 site across 1 country: United States